Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Iridex Corp
(NQ:
IRIX
)
1.800
+0.080 (+4.65%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Iridex Corp
< Previous
1
2
Next >
Iridex Comments on Changing Glaucoma Reimbursement Landscape
November 19, 2024
From
IRIDEX Corporation
Via
GlobeNewswire
Iridex Reports Third Quarter 2024 Financial Results
November 12, 2024
From
IRIDEX Corporation
Via
GlobeNewswire
Iridex to Report Third Quarter 2024 Financial Results on November 12, 2024
November 04, 2024
From
IRIDEX Corporation
Via
GlobeNewswire
IRIDEX Corp. (NASDAQ: IRIX) Records 52-Week High Tuesday Morning
October 31, 2023
Via
Investor Brand Network
Iridex Appoints Patrick Mercer as Chief Executive Officer
October 03, 2024
From
IRIDEX Corporation
Via
GlobeNewswire
Iridex Reports Second Quarter 2024 Financial Results
August 08, 2024
From
IRIDEX Corporation
Via
GlobeNewswire
Iridex Announces Convertible Note Financing
August 05, 2024
From
IRIDEX Corporation
Via
GlobeNewswire
Iridex to Report Second Quarter 2024 Financial Results on August 8, 2024
July 30, 2024
From
IRIDEX Corporation
Via
GlobeNewswire
Iridex Reports First Quarter 2024 Financial Results
May 14, 2024
From
IRIDEX Corporation
Via
GlobeNewswire
Iridex to Report First Quarter 2024 Financial Results on May 14, 2024
May 08, 2024
From
IRIDEX Corporation
Via
GlobeNewswire
Iridex Reports Fourth Quarter and Full Year 2023 Financial Results
March 26, 2024
Advances strategic review to unlock shareholder value
From
IRIDEX Corporation
Via
GlobeNewswire
Iridex Schedules Fourth Quarter and Full Year 2023 Financial Results and Update on Strategic Review Process for March 26, 2024
March 20, 2024
From
IRIDEX Corporation
Via
GlobeNewswire
Iridex Corporation Receives European Patent on MicroPulse Technology
February 06, 2024
The Advanced Short Pulse Laser System
From
IRIDEX Corporation
Via
GlobeNewswire
Iridex Announces First Patient Enrollment in MicroPulse® TLT Clinical Study Conducted in Collaboration with Imperial College Healthcare NHS Trust
January 24, 2024
From
IRIDEX Corporation
Via
GlobeNewswire
Iridex Launches New Iridex 532® and Iridex 577® Lasers in US Market Marking 35 Years of Laser Innovation in Treating Retina Disorders & Glaucoma
January 11, 2024
From
IRIDEX Corporation
Via
GlobeNewswire
Iridex Confirms Medicare Administrative Contractors Retired Local Coverage Determinations that Restricted Cyclophotocoagulation
December 28, 2023
Action Retains Full Patient Access to MicroPulse® Transscleral Laser Treatment
From
IRIDEX Corporation
Via
GlobeNewswire
Iridex Corporation Announces Successful Appeal for Revision of Recent Medicare LCDs to Provide Broader Coverage of Cyclophotocoagulation
November 27, 2023
From
IRIDEX Corporation
Via
GlobeNewswire
Iridex Reports Third Quarter 2023 Financial Results and Business Update
November 14, 2023
From
IRIDEX Corporation
Via
GlobeNewswire
Iridex to Host Third Quarter Financial Results Conference Call on November 14, 2023
November 13, 2023
The Company also announced plans to present at Stifel Healthcare Conference
From
IRIDEX Corporation
Via
GlobeNewswire
Iridex to Report Third Quarter Financial Results on November 14, 2023
October 26, 2023
From
IRIDEX Corporation
Via
GlobeNewswire
Iridex Announces Strategic Review to Unlock Shareholder Value
August 29, 2023
From
IRIDEX Corporation
Via
GlobeNewswire
Iridex Reports Second Quarter 2023 Financial Results
August 10, 2023
From
IRIDEX Corporation
Via
GlobeNewswire
Iridex to Report Second Quarter Financial Results on August 10, 2023
July 27, 2023
From
IRIDEX Corporation
Via
GlobeNewswire
Iridex Reports First Quarter 2023 Financial Results
May 11, 2023
From
IRIDEX Corporation
Via
GlobeNewswire
Iridex to Report First Quarter Financial Results on May 11, 2023
April 27, 2023
From
IRIDEX Corporation
Via
GlobeNewswire
Iridex Reports Fourth Quarter and Full Year 2022 Financial Results
March 09, 2023
Achieves Record Quarterly Glaucoma Probe Sales and 6% Full Year Revenue Growth
From
IRIDEX Corporation
Via
GlobeNewswire
Iridex to Present at the 35th Annual Roth Conference
March 07, 2023
From
IRIDEX Corporation
Via
GlobeNewswire
Iridex Introduces New Research and Showcases Five Events at the AGS Meeting
March 02, 2023
From
IRIDEX Corporation
Via
GlobeNewswire
Iridex to Report Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023
February 23, 2023
From
IRIDEX Corporation
Via
GlobeNewswire
Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2022
January 10, 2023
Achieves Record Quarterly Glaucoma Probe sales and 6% Full Year Revenue Growth
From
IRIDEX Corporation
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
